Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FYB201 PFS Ocular Safety and Usability Study
NCT06708624Phase 4Completed
- Sponsor
- Formycon AG
- Start
- Jun 2024
- Primary completion
- Aug 2024
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), macular edema, retinal vein occlusion (RVO), sponsored by Formycon AG. Started Jun 2024; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)macular edemaretinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT06708624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06708624.